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Abstract The role of drotrecogin
alfa (activated) (DAA) in severe
sepsis remains controversial and cli-
nicians are unsure whether or not to
treat their patients with DAA. In
response to a request from the Euro-
pean Medicines Agency, Eli Lilly
will sponsor a new placebo-controlled
trial and history suggests the results
will be subject to great scrutiny. An
academic steering committee will
oversee the conduct of the study and
will write the study manuscripts. The
steering committee intends that the
study will be conducted with the
maximum possible transparency; this
includes publication of the study
protocol and a memorandum of
understanding which delineates the
role of the sponsor. The trial has the
potential to provide clinicians with
valuable data but patients will only
beneﬁt if clinicians have conﬁdence
in the conduct, analysis and reporting
of the trial. This special article
describes the process by which the
trial was developed, major decisions
regarding trial design, and plans for
independent analysis, interpretation
and reporting of the data.
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Introduction
The incidence of severe sepsis is increasing and mortality
rates remain high. Whilst the case fatality rate has
decreased modestly, the overall number of deaths is still
increasing [1, 2]. Severe sepsis affects approximately
10 ± 4% of ICU patients, and around 100 ± 50 persons
per 100,000 population [2–10]. The burden of disease and
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comparable to that of ischaemic heart disease [4].
As new treatments for patients with severe sepsis have
proven remarkably elusive [11], the publication of the
PROWESS trial reporting that drotrecogin alfa (activated)
(DAA) reduced mortality was met with considerable
enthusiasm[3–10,12,13].Subsequently,muchoftheinitial
enthusiasm has waned and opinion over DAA has become
polarized [14, 15]. Atits annualreview of DAAinFebruary
2007, the European Medicines Agency (EMEA) stated:
‘‘Taking all the available data together, the Committee for
Medicinal Products for Human Use (CHMP) considered
that the beneﬁt/risk balance of Xigris required additional
clariﬁcation and that there was a need for another clinical
trial to further prove the efﬁcacy of Xigris in the target
population….therefore a placebo-controlled study in
patients …withseveresepsisand documented organfailure
(e.g. MOD or vasopressor-dependent septic shock) when
treated within a strictly deﬁned time window, should be
performed to assert the beneﬁt/risk proﬁle of Xigris.’’ [16].
Eli Lilly and Company (Lilly) agreed to sponsor the
study and subsequently assembled an academic steering
committee to advise on the design the trial and interpret
its results. This article, written by the academic steering
committee, describes the scientiﬁc and academic back-
ground to the study and is accompanied by publication of
the full study protocol as an on-line supplement. Addi-
tionally, it presents the memorandum of understanding
(MoU) delineating the relationship between the steering
committee and the sponsor. The MoU recounts the pro-
cesses by which the steering committee, the independent
academic statistical centre (ASC) and the data monitoring
committee (DMC) were established and formalizes the
respective roles of the sponsor and these committees in
the conduct of the trial. The processes and relationships
described in the MoU are intended to ensure that the study
will be designed, conducted, and analysed to the highest
possible scientiﬁc standards, and be reported transpar-
ently. The primary goal for the SC is to supervise the
design, conduct and analysis of a clinical trial that seeks
to answer the crucial question: ‘‘Does DAA reduce mor-
tality in patients with severe septic shock?’’
Background
The PROWESS study, the ﬁrst phase III placebo-controlled
randomised controlled trial of DAA, was stopped early
following a second planned interim analysis when 1,690 of
the planned 2,280 subjects had been enrolled. The trial
reported an absolute reduction in 28-day all-cause mortality
of 6.1% (a relative risk reduction [RRR] of 19.4%) [12].
Although the overall trial result was statistically sig-
niﬁcant, an FDA advisory committee noted several
concerns; in particular, approximately half way through
recruitment the protocol had been amended and the drug
manufacturing process changed and treatment with DAA
appeared more beneﬁcial after these changes (Fig. 1).
Additionally, the FDA advisory committee evaluated
the treatment effect within subgroups and concluded that
there was no apparent beneﬁt in subjects at lower risk of
death as indicated by lower APACHE II scores or in those
patient with single organ dysfunction at baseline [17].
The FDA advisory committee split 10:10 on whether
DAA should be approved for clinical use [18]. The FDA
received statistical advice that the variable treatment effect
observed over the course of the trial would be expected in
approximately 8% of clinical trials and that the trial results
did not appear to be due to the mid-trial protocol amend-
ment or the change in the drug manufacturing process
[19]. On 21 November 2001, the FDA licensed DAA but
only for the treatment of patients with severe sepsis and a
high risk of death (as determined, for example, by the
APACHE II score), and requested additional studies in
children and in adult patients with severe sepsis and a
lower risk of death [20]. In Europe, the European Medi-
cines Agency (EMEA) authorized DAA to be used for the
treatment of adult patients with severe sepsis with multiple
organ failure when added to best standard care; this
authorization was subject to annual review [16].
The additional trials requested by the FDA
Two additional placebo-controlled trials have been con-
ducted. The ADDRESS study in adult patients with severe
sepsis who were at a lower risk of death was stopped early
after 2,640 participants had been enrolled (Table 1)[ 21].
The independent DMC estimated the likelihood of dem-
onstrating a reduction in 28-day mortality to be less than
5%. Within the ADDRESS Trial mortality data were
available for 321 subjects (12.3%) who had a baseline
APACHE II score of 25 or more, the subgroup that
Fig. 1 Cumulative mortality rate over time in the PROWESS trial.
Solid black lines, drotrecogin alfa (activated) group; solid grey
lines, placebo group. The amended version of the protocol was
introduced at Line A, ﬁrst interim analysis occurred at Line B and
the second interim analysis at Line C. (Reproduced from Critical
Care Medicine 2004;32(12):2388 with permission)
1936appeared to beneﬁt in PROWESS; within this subgroup,
28-day mortality was 29.5% in those assigned to DAA
versus 24.7% in those assigned placebo, in-hospital
mortality rates were 32.3 and 32.7%, respectively [21].
Similarly, there was no reduction in mortality in the
subgroup of patients within ADDRESS who had multiple
organ dysfunction at baseline [21].
Between November, 2002 and April, 2005, the
RESOLVE trial randomly assigned children with sepsis-
induced cardiovascular and respiratory failure to receive
placebo or DAA [22]. The study was stopped after the
second interim analysis when 477 participants had been
enrolled when the independent DMC advised that the
likelihood of demonstrating a beneﬁcial effect of DAA
was low (Table 1)[ 22].
Evidence of harm
Whilst the efﬁcacy of DAA is now the subject of much
debate, the evidence that DAA increases the risk of
clinically signiﬁcant bleeding is consistent across trials
(Table 2). In ENHANCE, an open label clinical evalua-
tion where DAA was given to patients who satisﬁed the
entry criteria for the PROWESS Study, the serious
bleeding rate was 5.5%, somewhat higher than that seen
in the subjects who received DAA in the PROWESS
study [23]. Outside clinical trials off-label use may be
common and the incidence of bleeding may be increased.
In one clinical series, the incidence of bleeding was
10.9% and patients who received DAA and suffered
bleeding were more likely to die than those who received
DAA and did not bleed [24]; in the absence of a control
group assessment of how much bleeding is attributable to
the administration of DAA is not possible.
Expert commentary and the implications for patients
Results of these studies and the split vote of the FDA
advisory committee generated considerable controversy
and calls for a conﬁrmatory trial were made as early as
2002 [25]. The results of the ADDRESS and RESOLVE
studies resulted in further calls for another placebo con-
trolled trial [26–30]. The recent Cochrane review and
meta-analysis also questioned whether DAA should be
used to treat patients with severe sepsis and a high risk of
death, describing the evidence of efﬁcacy as ‘‘very weak’’
[30].
Furthermore, all three placebo-controlled trials were
stopped early; the PROWESS study was stopped for
efﬁcacy, an approach that tends to overestimate the ben-
eﬁcial effects of treatments [31, 32].
With expert opinion divided on the balance of the
beneﬁts and risks of treating patients with DAA, clinical
use has varied markedly between individual hospitals and
clinicians with many eligible patients not receiving the
drug [33–35]. The variable use of DAA has serious
implications for patients; if DAA does reduce the risk of
death then many patients are being denied an effective
treatment and dying unnecessarily; conversely, if DAA
does not reduce the risk of death, other patients are being
treated with an ineffective and expensive agent that may
cause clinically signiﬁcant bleeding.
Table 1 Results of placebo controlled randomised trials of drotrecogin alfa (activated)
Trial Actual/Planned
recruitment
% of planned
recruitment
% Assigned
DAA who Died
% Assigned
Placebo who Died
RR DAA vs.
Placebo
95% CI
for RR
PROWESS All patients 1,690/2,280 74.1% 24.7% 30.8% 0.80 0.69–0.94
PROWESS APACHE II\25 873 NA 18.8 19.0 0.99 0.75–1.30
PROWESS APACHE II[24 817 NA 30.9% 43.7% 0.71 0.59–0.85
PROWESS single organ failure 418 NA 19.5% 21.2% 0.92 0.63–1.35
PROWESS[1 organ failure 1,271 NA 26.5% 33.9% 0.78 0.66–0.93
ADDRESS: All patients 2,640/11,444 23.1% 18.5% 17.0% 1.09 0.92–1.28
ADDRESS APACHE II[24 321 NA 29.5% 24.7% 1.22 0.85–1.74
ADDRESS[1 Organ failure 862 NA 20.7% 21.9% 0.94 0.73–1.22
RESOLVE 477/6,000 8.0% 17.2% 17.5% 0.98 0.66–1.46
DAA Drotrecogin alfa (activated), RR relative risk, 95% CI = 95% conﬁdence interval, NA not applicable
Table 2 Serious bleeding rates in clinical trials of drotrecogin alfa
(activated)
Study Placebo n (%) DAA n (%) P
PROWESS 17(2.0) 30(3.5) 0.06
PROWESS (CNS) 1(0.1) 2(0.2) NS
ADDRESS 28(2.2) 51(3.9) 0.01
ADDRESS (Day 0–6) 15(1.2) 31 (2.4) 0.02
ADDRESS (CNS) 5(0.4) 6 (0.5) 0.72
RESOLVE 16(6.8) 16 (6.7) 0.97
RESOLVE (Day 0–6) 8(3.4) 98 (3.8) 0.83
RESOLVE (CNS) 5(2.1) 11 (4.6) 0.13
ENHANCE – 155 (6.5) –
Day 0–6: any serious bleeding event occurring during the DAA
infusion period
CNS central nervous system bleeding
1937Can an industry-sponsored trial resolve
this controversy?
It seems clear that the current controversy can only be
resolved by additional randomised placebo-controlled
trials. As industry sponsored trials tend to report more
favourable results than independent research [36, 37],
and as some clinicians will be concerned by allegations
that Lilly funded the Surviving Sepsis Campaign and
used it to market DAA [38, 39], the most credible trial
for all concerned would not be funded or conducted by
Lilly. Ideally, the trial would be conducted by indepen-
dent academic clinical trialists who would be responsible
for the data, conduct the statistical analysis, interpret the
results and write the study manuscripts. One such
investigator initiated and trial of DAA, funded by the
French government, is planned to run in parallel with the
Lilly-sponsored PROWESS-SHOCK trial [40]; both tri-
als will focus on patients with persistent septic shock.
These two trials in combination, be they positive or
negative, have great potential to settle this controversy.
As the PROWESS-SHOCK trial is being sponsored by
Lilly at the behest of the EMEA, it will fall short of some
commentators’, and our, vision of the most credible trial.
With this in mind, the steering committee has sought to
develop trial processes that can give clinicians and
patients conﬁdence in the trial results; we describe below
the process by which the trial was developed, some of
the major decisions made regarding trial design, and
plans for an independent analysis and reporting of the
data.
The PROWESS-SHOCK Trial
Organizational structure and role of the study sponsor
(Lilly)
Lilly has appointed a contract research organization
(Parexel International) to be responsible for the day-to-day
conduct of the study at each participating centre. At Lilly’s
invitation,DrsTaylorThompsonandMarcoRanieriagreed
toact as co-principal investigators forPROWESS SHOCK
and co-chair an academic steering committee. Addition-
ally, patient recruitment and protocol adherence will be
scrutinized by a clinical coordinating centre; the clinical
coordinating centre is located at Vanderbilt University and
is commercially contracted by Lilly to provide these ser-
vices.Thesteeringcommitteeisnotprivytothetermsofthe
contract but is satisﬁed that the study design prevents the
clinical coordinating centre from introducing bias into the
study.ThestatisticalanalysiswillbeperformedbybothEli
Lilly and an academic statistical centre and the safety of
trial participants will be overseen by an independent data
monitoring committee (DMC) (see Appendix 1), The
members of the DMC will be reimbursed at an hourly rate
($250–$350/h) for participation in conference calls, and
face to face meetings addressing data monitoring issues
related to the PROWESS-Shock trial. The relationship
between Lilly and the study committees is governed by a
signed MoU (see text box).
Memorandum of Understanding
1. The two principal investigators for the PROWESS–SHOCK
study, Dr Thompson and Dr Ranieri, were invited to Co-Chair
the committee by Eli Lilly and Company (Lilly). The principal
investigators selected the other seven members of the steering
committee (SC) in cooperation with Lilly. The principal
investigators independently approved the members and had the
right to veto members proposed by Lilly. Lilly representation in
the SC will be limited to three ex ofﬁcio non-voting members.
2. The steering committee in collaboration with medical experts
from Lilly designed the protocol for PROWESS-SHOCK, after
Lilly had come to an initial agreement with the Committee for
Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMEA) to study patients with septic shock.
Lilly provided analyses from their sepsis database to assist
protocol design and provided input regarding statistical and
regulatory aspects of the study. The two principal investigators
led the protocoldesign meetings and approvedthe ﬁnalprotocol.
Lilly did not have the right to veto any steps of this process.
3. Dr. Ranieri recommended the chair of the Data Monitoring
Committee (DMC) and invited Dr. Slutsky to participate. Dr.
Slutsky, the two principal investigators, and Lilly
recommended members of this committee. Dr. Slutsky
approved the ﬁnal membership of the committee and had the
right to veto members proposed by Lilly.
4. The two principal investigators identiﬁed an academic statistical
center that (subject tocontractual agreement) will be responsible
for reviewing and approving the statistical analysis plan,
including all of the prospectively deﬁned analyses for efﬁcacy
and safety. The plan will be ﬁled with the FDA prior to the data
being unblinded and at the same time it will be made freely and
publicly available on an academic website. The academic
statistical center will be responsible for conducting the primary
analysis of the study data, and preparing the main study report
for the SC to create the primary manuscript, and any additional
analyses of the study data for subsequent manuscripts that in the
view of the SC are material to understanding the efﬁcacy and
safety of drotrecogin alfa (activated). The academic statistical
group will also be responsible for performing any post-hoc
analyses requested by the steering committee. The members of
the academic statistical center will have unfettered access to the
full study database and to the randomisation code at the time the
study randomisation code is broken. Eligible members of the
academic statistical center will be co-authors on study
manuscripts.
Statisticians appointed by Lilly will independently conduct the
same analyses and any discrepancies will be resolved to the
satisfaction of both parties. All documents required for
regulatory purposes will be prepared by Lilly.
5. The monthly SC meetings via teleconference and/or all face-to-
face meetings will include an open session with Lilly experts
and closed meetings independent of Lilly. The principal
investigators are responsible for documenting any discussions
that occur during the closed meetings of the SC.
1938Study design and goals
PROWESS-SHOCK will be a concealed, randomised
placebo-controlled trial in which patients, care-givers,
data collectors, statisticians, the study steering committee,
and the clinical coordinating centre will be blinded.
Whilst mindful of the results of the PROWESS,
ADDRESS and RESOLVE studies, and Lilly’s obliga-
tions to drug registration agencies, the primary goal of the
trial is to provide clinicians with robust evidence
regarding the efﬁcacy and safety of DAA in a clearly
deﬁned and clinically important patient population.
Proposed time-lines for the trial are to start recruit-
ment in March 2008, complete recruitment in July 2010
and have 28-day mortality data available for public dis-
semination by the end of 2010.
Choice and rationale for study population (Protocol
Sect. 4.1)
The trial must satisfy regulatory requirements but equally
it must provide clinicians with a clearly identiﬁable patient
population to which the study results, be they positive or
negative, can be applied. The EMEA obliged Lilly to
complete a trial in patients ‘‘with severe sepsis and doc-
umented organ failure (e.g. multiple organ dysfunction
[MOD] or vasopressor dependent septic shock)’’. The
steering committee has elected to make persistent vaso-
pressor-dependent septic shock (deﬁned as the continuous
requirement for a vasopressor above a minimum threshold
dose for at least four hours) the key inclusion criterion as
such patients are clearly identiﬁable in clinical practice
and appeared to beneﬁt in the PROWESS trial. They also
represent the majority of patients that clinicians who use
DAA treat with the drug [41]. Standard deﬁnitions will be
used to identify patients with severe sepsis [42]. In addi-
tion, treatment with the vasopressor must be continued
through the time required to obtain informed consent and
for the study pharmacist to be ready to prepare the study
drug; patients’ whose septic shock has resolved during this
time will not be eligible for randomisation. Furthermore,
patients must have one further clinical sign consistent with
hypoperfusion (Table 3). The patients within the PROW-
ESS study who most closely satisﬁed these inclusion
criteria had a 28-day mortality of 29.3% for those assigned
to DAA and 37.6% for those assigned placebo (RR 0.78,
95% CI 0.63–0.96; Lilly—data on ﬁle). The inclusion
criteria are listed in Table 3; based on these inclusion
criteria, we estimate a placebo mortality rate of 35%. Thus
a study of 1,500 patients will provide 80% power to detect
a relative risk reduction of 20% with an a of 0.05.
As a further safeguard to ensure as far as possible that
only eligible patients enter the trial, all patients will be
screened by a clinical coordinating centre prior to ran-
domisation. The staff of the clinical coordinating centre
(CCC) will review a checklist of inclusion and exclusion
criteria with site investigators or coordinators and must
approve randomisation. Reasons for advising against
randomisation will be recorded and reviewed monthly by
the academic steering committee. As should be the case in
any randomised controlled trial, treatment allocation will
be concealed with local investigators and CCC staff
blinded to the randomisation sequence so that decisions to
include or exclude patients will be made with no
knowledge of the patient’s potential treatment group. To
minimize the risk of a centre effect and reduce the effect
of an imbalance in concomitant treatments between the
two groups, randomisation will be stratiﬁed by centre. As
far as is practical, the use of concomitant therapies that
are likely to inﬂuence the outcome from septic shock will
be captured in the case report form and reported.
To reduce the risk of recruitment bias, participating
centres conducting competing trials in patients with septic
Text box continued
6. The sponsor has pledged to make public, after publication of
the main paper, the ﬁnal study report for the study which will
include the following components: Introduction, Full Protocol,
Investigational Plan, Statistical Methods, Disposition of
Patients, Protocol Violations, Efﬁcacy Evaluations, Safety
Evaluations, and Tables of baseline and on study variables as
well as analyses of all outcomes, relevant Figures and Graphics,
and Final Conclusions. In the two years following publication
of the main paper, the academic statistical group will provide
additional analyses of the full database as requested by any
member of the public and approved by the SC. The SC will
develop procedures for reviewing public requests, judging the
merit of these requests for additional analyses, and adjudicating
duplicate requests for access to the database. Lilly will not have
the right to veto any requests the SC approves. The cost of any
additional analysis will be paid by the person or group
requesting the analysis.
7. The two principal investigators are responsible for the main
publications from this study. There will be no scientiﬁc writer
from Eli Lilly and Company for the principal manuscript or
subsequent manuscripts approved by the SC. Appropriate co-
authors from the sponsor will be included if they meet standard
criteria for authorship. However, (a) the two principal
investigators and the independent members of the steering
committee will be responsible for ﬁnal approval of the content
and conclusions of the manuscripts; (b) the manuscripts will be
submitted by the two principal investigators not by Lilly; (c)
Lilly will not have the right to veto any steps of this process.
8. Lilly will remunerate the members of the SC and DMC or their
employing institutions for time spent performing committee
activities and the amounts paid to each committee member will
be stated at any major presentation of study results and in all
manuscripts reporting study results that are authored by the SC.
Time spent in preparation of manuscripts and lecture materials
will not be remunerated by Lilly. Any lecture materials
regarding the conduct or results of the study will be clearly
identiﬁed as either prepared and approved by the Steering
Committee or prepared by Lilly independent of the steering
committee.
9. Following publication of the primary manuscript SC and DMC
members will have an absolute right to make public comment
in any medium should they have concerns about the design,
conduct or analysis of the study, or the interpretation or
presentation of the study data.
1939shock will use a predetermined random or sequential
selection procedure for deciding which trial a patient
enters when a patient is eligible for more than one trial.
Short term and longer term outcomes
(Protocol Sect. 6.1)
Theprimaryoutcomemeasurewillbeall-causemortalityin
the intention-to-treat population (all patients randomised
regardless of whether they received all or any study treat-
ment) 28-days after randomisation. Survival and quality of
lifewillbeassessedforupto180 daysafterrandomisation.
Thesecondaryoutcomemeasuresarelistedintheprotocol.
Adaptive design to allow an increase in sample
size if overall mortality is lower than expected
(Protocol Sect. 8.1.1)
Intensive care treatment of patients with severe sepsis and
septic shock is changing and the case fatality rate is
decreasing [1, 2, 43]. Against this background, an accurate
prediction of the placebo group mortality is difﬁcult.
Therefore, the steering committee has made provision for
the study statisticians to calculate the blinded mortality
rate when approximately 750 patients have been enrolled,
if the overall mortality rate is less than 30% the sample
size may be increased by up to 500 subjects.
Rationale for conservative efﬁcacy stopping rule
and absence of ‘‘futility’’ stopping rule
(Protocol Sect. 8.2.8)
The DMC and the steering committee separately discussed
the principles for interim analyses and stopping rules; both
committees were in favour of very conservative stopping
rules and that the trial should not be stopped for futility.
The DMC recommended the ﬁnal stopping rules for the
study and these were accepted by the steering committee.
Two interim analyses are planned; the ﬁrst after
approximately one-third and the second after two-thirds
of the planned number of subjects have completed
28 days of follow up. The DMC will be supplied with
unblinded data; these data will not be seen by the steering
committee or the sponsor. For the ﬁrst interim analysis, no
efﬁcacy stopping rules are planned. We reasoned that
only an implausibly large beneﬁt of DAA over placebo
would stop the trial after recruitment of 500 subjects and
that such an effect should be regarded with great scepti-
cism [44]. In addition, it is highly likely that the number
of deaths accrued would fall below that recommended for
stopping such a trial [31]. It is clear that seemingly con-
vincing treatment effects observed early in trials may not
be sustained when trials are allowed to complete
recruitment as planned [32, 44].
As one experienced commentator stated ‘‘Decisions on
early stopping (or not) need to be based on wise judg-
ments interpreting the totality of available evidence, both
in the current trial (considering primary and other efﬁcacy
outcomes and safety issues) and in other external evi-
dence (especially from related trials). Accordingly, a
statistical stopping boundary is only one useful objective
component in an inevitably more challenging decision
making process.’’ [32] Additionally, in the event that the
mortality in the DAA group was lower at the ﬁrst interim
analysis, we consider it ethical to continue the trial as the
proportion of eligible patients receiving DAA outside the
trial is likely to be much lower than the 50% within the
trial [24, 33].
For the second interim analysis at 1,000 patients, an
efﬁcacy stopping guideline is proposed if DAA is superior
to placebo at a p value of B0.001 and if at least 250 deaths
have occurred [31]. At this point, we reason that such an
effect would be compelling and would be sufﬁcient to
convince many clinicians to change their practice.
We decided against a formal futility stopping guide-
line because of the importance to determine with as much
Table 3 Inclusion criteria
Inclusion criteria to obtain informed consent
1. Aged C 18 years old
2. Must have an infection requiring intravenous antimicrobial
therapy
3. Must meet at least two of the four systemic inﬂammatory
response syndrome (SIRS) criteria.
4. Must have septic shock, deﬁned as:
(a) The patient must have received intravenous ﬂuid resuscitation
of C 30 mL/kg administered within the time period spanning the
4 hours before and 4 hours after initiation of vasopressor therapy.
(b) The patient must have a continuous requirement for at least one
of the vasopressors listed below at the dose shown below for at
least four hours:
Norepinephrine C 5 mcg/min
Dopamine C 10 mcg/kg/min
Phenylephrine C 25 mcg/min
Epinephrine C 5 mcg/min
Vasopressin C 0.03 units/min
(c) The patient must meet at least 1 of the following criteria
consistent with hypoperfusion during the 36 hours prior to study
entry:
Metabolic acidosis: base deﬁcit C 5.0 mmol/L or venous
bicarbonate\18 mmol/L or lactate C 2.5 mMol/L.
Urine output\0.5 mL/kg h
-1 for 1 hour or a 50% increase in
creatinine from a known baseline level.
Acute hepatic dysfunction: AST or ALT[500 IU/dL or
bilirubin[2 g/dL.
Inclusion criterion to proceed to randomisation
5. Patients must remain vasopressor dependent throughout the
pretreatment period and through the time of randomisation with
the goal of maintaining a systolic blood pressure of
approximately 90 mm Hg or higher or a mean arterial pressure of
65 mm Hg or higher with reasonable attempts made to wean the
patient from vasopressor support, if applicable. (Note: dopamine
at doses\5 mcg/kg/min does not fulﬁl the criteria for
vasopressor dependency.)
1940certainty as possible whether DAA is ineffective and thus
discontinue its use in usual care. However, the indepen-
dent DMC may recommend the trial be stopped for safety
concerns at any time.
A comparison of the PROWESS and PROWESS-
SHOCK trials is presented in Table 4.
Safety monitoring (Protocol Sect. 6.2)
Site investigators are responsible for reporting all serious
adverse events and any non-serious bleeding or throm-
botic events that occur within 28 days of randomisation.
After 28 days, only serious adverse events that the site
investigator considers to be related to the study drug, the
drug delivery system, or a protocol procedure are repor-
ted. The DMC will be provided with monthly reports
regarding safety data. If after reviewing these reports the
DMC has concern regarding the incidence of adverse or
serious adverse events in either arm of the study, the
DMC can request and will be granted an unscheduled
review of unblinded safety data. The DMC will also
review unblinded data at all scheduled interim analyses.
Ethics of a placebo-controlled trial of licensed drug
in high risk population: identifying study sites
with equipoise/uncertainty
There are a number ethical issues and practical challenges
in conducting a placebo controlled trial of a licensed drug
within the current indication for use and in a vulnerable
patient population. Central to their consideration is that the
evidence in favour of DAA must now be considered
equivocal, numerous respected commentators have called
for another such trial [25–30], and currently relatively few
patientswithseveresepsisreceiveDAA[24,33–35].From
an individual patient perspective, any patient for whom the
treating clinician considers DAA to be clearly indicated or
contra-indicated will be excluded from the trial, thus the
trial will only recruit patients where the senior treating
clinician has clinical equipoise or substantial uncertainty
over the balance of the beneﬁts and risks associated with
treatment with DAA. An important criterion for the
selection of trial centres is that the local clinicians are
uncertain about the beneﬁts and risks of treatment with
DAA and consider it ethical to treat eligible patients with a
blinded study drug that may be either DAA or placebo.
Another risk to the conduct of the trial is that clini-
cians may wish to treat patients who are deteriorating
whilst receiving study drug with commercially available
DAA; this risk will be minimized by selecting centres
where clinicians are uncertain about the beneﬁts and risks
of treatment with DAA and where clinicians report that
this uncertainty has resulted in minimal use of DAA.
These aspects were assessed in a questionnaire as part of
the participating centre evaluation, the document evalu-
ating potential participating centres is reproduced in
Appendix 2. Additionally, the physical properties of DAA
mean that it is possible for caregivers to become
‘‘unblinded’’ to treatment allocation and this might theo-
retically inﬂuence the use of concomitant treatments
(such as commercially available DAA) or willingness to
continue active medical treatment. The use of commer-
cially available DAA and the issuing of ‘‘DNR’’ orders
will be monitored during the trial and reported.
Maximizing clinician acceptance of the PROWESS
SHOCK results
The controversy over the PROWESS study results has
been documented elsewhere [19, 25, 26, 38]. We hope to
reduce the risk of similar controversy following the cur-
rent trial; we created conservative efﬁcacy stopping
guidelines to assure a more precise estimate of the overall
treatment effect and reduce the concern that trials stopped
early overestimate treatment effects [31, 45]. The trial
Table 4 Comparison of PROWESS and PROWESS-SHOCK trials
PROWESS PROWESS-SHOCK
Inclusion criteria Severe Sepsis (62.5% in shock) Persistent septic shock
Initial ﬂuid resuscitation C500 mL C30 mL/kg
Primary end point 28-day all-cause mortality 28-day all-cause mortality
Primary analysis ‘‘As Treated’’ conducted by Sponsor ‘‘Intention-to-treat’’ conducted by Independent
ASC and Sponsor
Selected secondary
end points
Changes in plasma D-dimer
and Serum IL-6
28 Day mortality by protein-C class;
organ failure; 90 and 180 day mortality
Planned sample size 2,280 patients (stopped @ 2nd interim
analysis for efﬁcacy N = 1,690 patients)
1,500 (option to enroll 2000 if aggregate
mortality @ 750 patients\30%)
Efﬁcacy stopping
(By independent DMC)
At both interim analyses Guidelines per
O’Brien-Fleming; Lan and Demets
No efﬁcacy guidelines at 1st interim;
consider stopping at 2nd interim
if P B 0.001 and C 250 deaths overall
* The ‘‘as treated’’ analysis included all patients who received the infusion for any length of time; ASC Academic Statistical Center
1941will use an academic clinical coordinating centre to assist
investigators in recruiting appropriate patients and in
following the protocol precisely. The clinical coordinat-
ing centre will serve as a resource for study procedures
which should minimize the learning curve and its poten-
tial impact on the trial results [46]. Finally, we hope that
publishing the trial protocol, the memorandum of under-
standing governing the relationship between Lilly and the
study committees and full disclosure of all prior and
present relationships relevant to the trial, together with
plans for independent analysis of the data, we will provide
clinicians and regulators with sufﬁcient information to
allow them to fully evaluate the conduct of the trial and to
interpret the results.
Summary
Although the initial report of the PROWESS study sug-
gested a signiﬁcant breakthrough in the search for
treatments for patients with severe sepsis, the subsequent
controversy surrounding the conduct of that trial and the
subsequent negative trials, have left many clinicians
uncertain whether to treat their patients with DAA or not.
There have been a number of calls for another placebo
controlled trial some of which have speciﬁcally called for
a trial run by a not-for-proﬁt organisation [24]. Whilst
Lilly will sponsor a new trial, the steering committee has
put in place processes which it hopes will increase the
transparency with which the trial is conducted so that the
trial can provide robust evidence that will be acceptable to
clinicians. This is an ethical imperative, as only by pro-
viding credible evidence and resolving this controversy
can we serve the best interests of our patients.
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Appendix 2
Potential investigator questionnaire
Eli Lilly and Company is sponsoring a placebo controlled
study to further deﬁne the beneﬁts and safety proﬁle of
Xigris
 , drotrecogin alfa (activated), in adult patients
with persistent septic shock. PAREXEL is the contract
research organization for this study.
PAREXEL and Lilly are in the process of selecting
qualiﬁed investigators and investigative sites in select
countries around the world. Please review the protocol
highlights and complete and return the questionnaire if
you are interested in participating in this study.
Investigator selection will be completed this fall.
Patient enrollment will begin in the ﬁrst quarter of 2008.
Study drug drotrecogin alfa (activated) or placebo.
Study objectives The study objectives are to investigate
efﬁcacy (28-day all-cause mortality) and safety in adult
patients with septic shock that are treated with either
drotrecogin alfa (activated) or placebo.
Study design Patients will be randomly (1:1) assigned to
either the drotrecogin alfa (activated) or placebo treat-
ment group.
The study will enroll adult patients who meet the
following criteria:
(a) Evidence of an infection and the presence of SIRS
(b) Presence of septic shock
• The patient must have received C 30 mL/kg intrave-
nous ﬂuid resuscitation
• The patient must have a continuous requirement for
vasopressor support for at least 4 hours at a minimum
dose (Norepinephrine C 5 mcg/min, or similar dose of
dopamine, phenylephrine, epinephrine, or vasopressin)
(c) At least one clinical sign consistent with hypoperfu-
sion (sepsis-induced)
• Metabolic acidosis (base deﬁcit C 5.0 mEq/L, venous
bicarbonate\18 mEq/dL or lactate C 2.5 mMol/L)
• Renal injury (urine output\0.5 mL/kg/h for 1 hour or
a 50% increase in creatinine)
• Acute hepatic dysfunction (AST or ALT[500 IU/dL
or bilirubin[2 g/dL).
(d) Study drug infusion must begin within 24 h of septic
shock onset (i.e. after initiation of vasopressor
therapy) and within 36 h of any non-cardiovascular
sepsis-induced organ dysfunction.
If you are not the proper person to review and com-
plete this questionnaire, kindly forward this to the
appropriate person at your institution.
19421. Considering the current standard practice in your ICU in regards of use, would you be willing to 
participate in this phase III trial in which 50% of enrolled patients with septic shock will NOT 
receive rhAPC due to the placebo control arm of this trial?
  YES   NO
2. What is the average monthly census of adult patients with septic shock treated at your site 
(ED/ICUs where you are able to screen patients for enrollment)?  _________ per month
3. How many fully supported beds (invasive monitoring, ventilator support, vasopressor 
administration, renal replacement therapy) are available to you for screening and enrolling 
patients?   __________beds
What is the number of beds in each ICU? 
Medical: __________  
Surgical: __________ 
       Other (i.e. Trauma, Burn, Cardiac; Neurological):    __________
4. From what type of ICU will you be enrolling patients?  Estimate percentage from each ICU type.
Medical     _____% Burn         _____% Neurological    _____%
Surgical    _____% Cardiac     _____% Trauma            _____%
Other        _____ % specify type of unit______________________________
5. What type of healthcare provider is the Lead Investigator?
   Anesthesiologist                                 Critical-care/Pulmonary   Infectious Diseases  
Surgeon/ Surgical Intensivist               Other, Specify: :_ __ __ __ __ __ __ __ __ __ __ __ __ _
6. Number of co-investigators (who will be involved in key study activities such as consenting 
patients or making safety assessments) likely at your site: ____________
7. Does your site have a dedicated pharmacist or access to non-ICU staff to fulfill the unblinded 
pharmacist role?  
  YES   NO
        Is pharmacy coverage available 24 hours a day/7 days a week?     YES   NO
        Does the Pharmacy have access to a touch tone phone?      YES   NO
8. Does your site have at least one Research Nurse or Study Coordinator?    YES    NO
Complete for each coordinator who might participate in this study 1 2 3
Check if full time
Check if part time
Number of years serving as a Study Coordinator
Number of years at your site
9. Will your site have designated personnel screening 7 days a week?     YES   NO
10. Will your site have the ability to perform study related procedures and assessments 7 days a week?   
   YES    NO
11. What is your experience with past clinical trials with a severe sepsis/septic shock patient 
population?
Site Investigator Coordinator
PROWESS (F1K-MC-EVAD)
1943ENHANCE (F1K-MC-EVBF)
ADDRESS (F1K-MC-EVCL/M)
XPRESS (F1K-MC-EVBR)
EXTEND (F1K-MC-EVBQ)
Other non-Lilly severe sepsis/ septic shock trial
Other Critical Care Randomised Controlled trial 
None
12. Are there any sepsis clinical trials currently being run at your site or planned for 2008?  
 No              
 Yes – please specify type below
Interventional (device or medication) 
Observational
If yes, would you be willing to adhere to a screening schedule for each trial, i.e. limiting 
enrollment in this study to even number days and any competing study(ies) to odd number 
days?       YES   NO
13. This trial will utilize electronic data capture (eDC) rather than the traditional paper CRF method of 
data collection.  Please indicate the level of eDC experience key study team members have.
None Yes  If yes, # of eDC studies conducted in hospitalized patients 
Principal Investigator (PI)
SC
14. Computer and internet access are required to support an eDC study.  Please indicate which are 
currently available at your site.
Currently 
Available
Can/Would 
be Added
Cannot Be 
Obtained
High speed internet access within the hospital for the 
investigator/coordinator
High speed internet access in a remote location 
(where patient data could be entered) available to 
investigator/coordinator
15. Do you have the following equipment available at your institution?
a. Refrigerator in the pharmacy for storage of study drug in which temperature is monitored daily. 
 YES    NO
b. -20°   Freezer that does not automatically defrost for storage of patient samples in which   
temperature is monitored daily. 
 YES     NO
16. From time of initial submission to the E/IRB, how quickly do you feel the E/IRB would be able to 
review and approve (including protocol and consent) this study? 
  Within 2 weeks   Within 6 week    
  Within 4 weeks                Longer than 6 weeks, specify ________
17. What is the estimated total number of severe sepsis patients treated with commercial drotrecogin 
alfa (activated) in the ICU’s you will be screening?     Per month  or    _________ Per 
year  
194418. Do you follow a hospital/department policy for drotrecogin alfa (activated) use?   YES
NO
If yes, does the placebo controlled design of this study create conflicts with the drotrecogin alfa 
(activated) policy?   
Please describe: 
19. There will be a protocol addendum and consent document asking for the collection of a DNA 
sample and 3 proteomic samples. These stored samples will be handled in a manner compliant 
with standard privacy practices, but will not be de-identified. 
Will you participate in this addendum?  YES      NO Need more information
         If yes, what percentage of patients do you expect to be enrolled in the sample storage addendum 
at your site?  
   > 90%   50% – 90%                         < 50%
20. The availability of commercial drotrecogin alfa (activated) may influence the scientific accuracy 
and validity of the study results.  To minimize this potential impact to the trial, Lilly feels it is in 
the best interest of all involved to determine the level of clinical equipoise at sites that seek to 
participate in the planned study.
We thus ask you, as the lead investigator, to review the following clinical scenarios, and 
assess the current standard of care regarding drotrecogin alfa (activated) use at your institution 
by yourself and colleagues, using these ratings:
Drotrecogin alfa (activated): 
1. Never would be used in this situation
2. Rarely would be used in this situation
3. Sometimes would be used in this situation
4. Often would be used in this situation
Assume in the following clinical scenarios, each patient has a diagnosis of severe sepsis and 
meets your country’s regulatory indication for drotrecogin alfa (activated) use.
1. 72 year-old male with history of alcohol abuse and pneumococcal pneumonia requiring 
ventilator support to maintain oxygenation, and vasopressor support to maintain a SBP 
>90 mmHg.  
Answer:_______
2. 51 year-old female 12 hours post laparotomy and hemicolectomy for diverticulitis with 
perforation, patient requires vasopressor support and is anuric.
Answer:_______
3. 20 year-old female with meningococcemia, with septic shock requiring mechanical 
ventilation and in DIC.
Answer:_______
21. Are there certain patient types or conditions that you would object to randomizing into this study?
  Yes, for ethical reasons              Yes, efficacy is established               No
Conﬂict of Interest A statement by the authors concerning their
ﬁnancial relationship with regard to the subject of this paper is
available as Electronic Supplementary Material.
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